{"preliminary_commentary":{"by_channel":{"x_thread":68,"youtube":12,"podcast":11,"x_video":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04613596\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"KRYSTAL-7","nct_id":"NCT04613596","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=krystal-7-nct04613596. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Cohort 1a: Adagrasib twice daily (BID) in combination with pembrolizumab","label":"Phase 2 Cohort 1a: PD-L1 TPS <1%","type":"EXPERIMENTAL"},{"description":"Cohort 1b: Adagrasib BID monotherapy","label":"Phase 2 Cohort 1b: PD-L1 TPS <1%","type":"EXPERIMENTAL"},{"description":"Cohort 2: Adagrasib BID in combination with pembrolizumab","label":"Phase 2 Cohort 2: PD-L1 TPS ≥1%","type":"EXPERIMENTAL"},{"description":"Adagrasib BID in combination with pembrolizumab","label":"Phase 3 Cohort 3 Investigational Arm","type":"EXPERIMENTAL"},{"description":"Pembrolizumab","label":"Phase 3 Cohort 4 Comparator Arm","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-10-31","type":"ESTIMATED"},"conditions":["Advanced Non-Small Cell Lung Cancer","Metastatic Non-Small Cell Lung Cancer"],"enrollment":{"count":626,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Adagrasib","otherNames":["Pembrolizumab"],"type":"DRUG"},{"name":"Adagrasib","otherNames":[],"type":"DRUG"},{"name":"Adagrasib","otherNames":["Pembrolizumab"],"type":"DRUG"},{"name":"Adagrasib","otherNames":["Pemrolizumab"],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-13","lead_sponsor":"Mirati Therapeutics Inc.","official_title":"A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation","overall_status":"RECRUITING","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2028-10-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Phase 2: To evaluate the efficacy of Adagrasib monotherapy and in combination with pembrolizumab administered to patients having advanced/metastatic NSCLC.","timeFrame":"22 months"},{"measure":"Phase 3: To compare efficacy of Adagrasib in combination with pembrolizumab versus pembrolizumab","timeFrame":"36 months"}],"references":[],"start_date":{"date":"2020-12-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7","url":"https://clinicaltrials.gov/study/NCT04613596"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/krystal-7-nct04613596"}